Bile duct carcinoma
MONDO:0005496A carcinoma that arises from epithelial cells of the bile duct
Also known as: bile duct cancer, bile duct cancer (including cholangiocarcinoma), bile duct carcinoma, carcinoma of bile duct
3338 clinical trials for this condition and its sub-types, 20 tagged with Bile duct carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Bile duct carcinoma
-
Extrahepatic bile duct carcinoma 48 trials · 429 incl. sub-types
6 sub-types
- Extrahepatic bile duct adenocarcinoma 2 trials · 406 incl. sub-types Sub-types →
- Carcinoma of the ampulla of vater 29 trials · 65 incl. sub-types Sub-types →
- Distal biliary tract carcinoma 32 trials
- Carcinoma in situ of extrahepatic bile duct 0 trials
- Extrahepatic bile duct leiomyosarcoma 0 trials
- Extrahepatic bile duct squamous cell carcinoma 0 trials Sub-types →
-
Bile duct adenocarcinoma 17 trials · 416 incl. sub-types
1 sub-type
- Extrahepatic bile duct adenocarcinoma 2 trials · 406 incl. sub-types Sub-types →
-
Bile duct carcinoma in situ 0 trials
1 sub-type
-
Squamous cell bile duct carcinoma 0 trials
2 sub-types
Most studied deeper sub-types
-
New drug combo targets Hard-to-Treat cancers with genetic weakness
Disease control Recruiting nowThis early-stage trial is testing a new drug called IDE892, alone or with another drug (IDE397), in people with advanced solid tumors that have a specific genetic deletion (MTAP). The study aims to find safe doses and see if the drugs shrink tumors. It includes 260 adults with ca…
Phase 1 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New antibody drug combo targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called AZD8205, alone or with another drug (rilvegostomig), in people with advanced solid tumors like breast, ovarian, and lung cancers. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 460 adults whose c…
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug BNT329 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug called BNT329 in people with advanced solid tumors that have a specific marker (CA19-9). The main goals are to check safety and find the best dose. About 245 participants will take part. The drug works by targeting cancer cells and may help control tum…
Phase 1/2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New drug combo aims to fight deadly gallbladder cancer
Disease control Recruiting nowThis phase 2 trial is testing whether adding an experimental immunotherapy drug called ZG005 to standard chemotherapy (gemcitabine and cisplatin) can help people with advanced gallbladder cancer. About 60 participants will receive either the combination or standard treatment. The…
Phase 2 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New cocktail of drugs shows promise for tough bile duct cancer
Disease control Recruiting nowThis phase 2 trial is testing a combination of four drugs—two chemotherapy drugs (gemcitabine and oxaliplatin), a targeted therapy (donafenib), and an immunotherapy (tislelizumab)—in 93 people with advanced biliary tract cancer that has spread. The goal is to see if this mix can …
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New disposable scope aims to improve bile duct stone removal and diagnosis
Diagnosis Recruiting nowThis study is testing a new, single-use scope called the Dragonfly™ Digital Pancreaticobiliary System. It is designed to help doctors see inside the bile and pancreatic ducts during an endoscopy. The study will enroll up to 75 adults with bile duct stones or narrowings (stricture…
Phase 4 • Sponsor: University of Colorado, Denver • Aim: Diagnosis
Last updated Sep 05, 2026 00:00 UTC
-
New PET scan technique could sharpen cancer detection in the gut
Diagnosis Recruiting nowThis study is testing a new type of PET scan that uses special probes to highlight digestive system cancers, such as stomach, liver, colon, and pancreatic cancers. Researchers will enroll 400 adults to see how well this imaging method finds tumors and tracks their response to tre…
Sponsor: RenJi Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 08:07 UTC
-
Cancer care at home: a Game-Changer for patients?
Symptom relief Recruiting nowThis study compares giving cancer treatment at home versus in a clinic for 27 adults with various cancers in the Florida Panhandle. The goal is to see if home treatment is preferred and improves satisfaction, while also checking safety. Participants will receive their usual cance…
Phase 2 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Aug 01, 2026 00:00 UTC
-
Virtual reality goggles could be new tool against cancer pain
Symptom relief Recruiting nowThis study tests whether using virtual reality (VR) can reduce severe belly pain and improve quality of life in people with digestive tract cancers. 360 participants will be split into three groups: one using a skills-based VR program, one using distracting VR videos, and a contr…
Sponsor: Cedars-Sinai Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 09:07 UTC